Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

References

• Pletz MW, Bahrs C. [Pneumococcal vaccination]. Internist. 2021;62(8):807–815. doi: 10.1007/s00108-021-01100-2
   PubMed Web of Science ®Google Scholar
• Ambulant erworbene Pneumonie: Bundesauswertung zum Erfassungsjahr 2019. IQTIG–Institut für Qualitätssicherung und Transparenz im Gesundheitswesen B; 2020.
   Google Scholar
• Theilacker C, Sprenger R, Leverkus F, et al. Population-based incidence and mortality of community-acquired pneumonia in Germanys. PLoS One. 2021;16(6):e0253118. doi: 10.1371/journal.pone.0253118
   PubMed Web of Science ®Google Scholar
• Robert Koch Institut. SurvStat@RKI 2.0 Web-basierte Abfrage der Meldedaten gemäß Infektionsschutzgesetz (IfSG) 2021. Rober Koch Institut; 2021.
   Google Scholar
• Hanquet G, Krizova P, Dalby T, et al. Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe. Emerg Infect Dis. 2022;28(1):137–138. doi: 10.3201/eid2801.210734
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451. doi: 10.1016/S1473-3099(18)30052-5
   PubMed Web of Science ®Google Scholar
• van der Linden M, Imöhl M, Perniciaro S, et al. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLoS One. 2019;14(8):e0220453. doi: 10.1371/journal.pone.0220453
   PubMed Web of Science ®Google Scholar
• Ständige Impfkommission. Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2021. Epidemiologisches Bull. 2021;34:3–63.
   Google Scholar
• Hurley D, Griffin C, Young M, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2021;73(7):e1489–e1497. doi: 10.1093/cid/ciaa1045
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Press Release]. Vaxneuvance: pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed). [cited 2021 Oct 14]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vaxneuvance_en.pdf.
   Google Scholar
• European Medicines Agency. Apexxnar product infomation. 2022
   Google Scholar
• European Medicines Agency [Press Release]. Apexxnar (pneumococcal polysaccharide conjugate vaccine, 20-valent, adsorbed) an overview of apexxnar and why it is authorised in the EU. [cited 2020 Mar 2]. Available from: https://www.ema.europa.eu/en/documents/overview/apexxnar-epar-medicine-overview_en.pdf.
   Google Scholar
• Pfizer Inc. [Press Release]. U.S. FDA approves PREVNAR 20™, Pfizer’s pneumococcal 20-valent conjugate vaccine for adults ages 18 years or older. [cited 2021 Jun 8]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent
   Google Scholar
• Merck & Co. Inc. [Press Release]. Merck announces U.S. FDA approval of VAXNEUVANCE™ (pneumococcal 15-valent conjugate vaccine) for the prevention of invasive pneumococcal disease in adults 18 years and older caused by 15 serotypes. 2021 [cited 2021 Dec 16]. Available from: https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/
   Google Scholar
• Clutterbuck EA, Lazarus R, Yu L-M, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408–1416. doi: 10.1093/infdis/jis212
   PubMed Web of Science ®Google Scholar
• Davies LRL, Cizmeci D, Guo W, et al. Polysaccharide and conjugate vaccines to streptococcus pneumoniae generate distinct humoral responses. Sci Transl Med. 2022;14(656):eabm4065. doi: 10.1126/scitranslmed.abm4065
   PubMed Web of Science ®Google Scholar
• Pelton SI, Shea KM, Farkouh RA, et al. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015;15(1):470. doi: 10.1186/s12879-015-1162-y
   PubMed Web of Science ®Google Scholar
• Mahar E, Sprenger R, Diesing J, et al. Case Fatality risk and attributable costs in patients treated for community-acquired pneumonia in Germany: a population-based healthcare claims data cohort study. 2022. PREPRINT. doi: 10.2139/ssrn.4118607
   Google Scholar
• Statistisches Bundesamt (Destatis). Population: Germany reporting date, age years [Table 12411-0005]. 2022 [cited 2022 Feb]. Available from: https://www.destatis.de/DE/Home/_inhalt.html.
   Google Scholar
• Deb A, Podmore B, Barnett R, et al. Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany. Epidemiol Infect. 2022;150:e204. doi: 10.1017/S0950268822001182
   PubMed Web of Science ®Google Scholar
• Statistisches Bundesamt. Gesundheitsberichterstattung des Bundes. 2021. Available from: https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_menu_olap?p_uid=gast&p_aid=47092962&p_sprache=D&p_help=2&p_indnr=550&p_version=10&p_ansnr=38796254.
   Google Scholar
• Kuhlmann A, Treskova M, Graf von der Schulenburg J-M. Pneumokokkenerkrankungen bei Erwachsenen: Gesundheitsökonomische Evaluation unterschiedlicher Impfszenarien in Deutschland. Rober Koch Institut; 2016.
   Google Scholar
• Kuchenbecker U, Chase D, Reichert A, et al. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. PLoS One. 2018;13(5):e0197905. doi: 10.1371/journal.pone.0197905
   PubMed Web of Science ®Google Scholar
• Rieck T, Steffen A, Feig M, et al. Impfquoten bei Erwachsenen in Deutschland – Aktuelles aus der KV-Impfsurveillance. Epid Bull. 2022;49:3–23.
   Google Scholar
• Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125. doi: 10.1056/NEJMoa1408544
   PubMed Web of Science ®Google Scholar
• Mangen M-J, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407–1416. doi: 10.1183/13993003.00325-2015
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341–1348. doi: 10.1056/NEJMoa035060
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-Infected adults. N Engl J Med. 2010;362(9):812–822. doi: 10.1056/NEJMoa0903029
   PubMed Web of Science ®Google Scholar
• Patterson S, Webber C, Patton M, et al. A post hoc assessment of duration of protection in CAPiTA (community acquired pneumonia immunization trial in adults). Trials Vaccinol. 2016;5:92–96. doi: 10.1016/j.trivac.2016.04.004
   Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clinl Infect Dis. 2018;67(10):1498–1506. doi: 10.1093/cid/ciy312
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24. doi: 10.1016/j.jinf.2012.02.017
   PubMed Web of Science ®Google Scholar
• Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42–50. doi: 10.1016/j.eclinm.2018.12.007
   PubMedGoogle Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–321. doi: 10.1016/S1473-3099(17)30049-X
   PubMed Web of Science ®Google Scholar
• Reinert RR, Haupts S, van der Linden M, et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect. 2005;11(12):985–991. doi: 10.1111/j.1469-0691.2005.01282.x
   PubMed Web of Science ®Google Scholar
• Bahrs C, Kesselmeier M, Kolditz M, et al. Pneumococcal serotype distribution in adults with community-acquired pneumonia in Germany and coverage of an investigational 20-valent conjugate vaccine: a longitudinal analysis from the CAPNETZ cohort 2013-2018. 31st European Congress of Clinical Biology and Infectious Diseases; July 9–12, 2021. 2021.
   Google Scholar
• Hoshi SL, Shono A, Seposo X, et al. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly. Vaccine. 2022;40(49):7057–7064. doi: 10.1016/j.vaccine.2022.10.010
   PubMed Web of Science ®Google Scholar
• Leidner AJ Summary of three economic models assessing pneumococcal vaccines in US adults. In: ACIP Meeting. Atanta (GA): National Center for, I, Respiratory Diseases. Immunization Services, D; 2021.
   Google Scholar
• Chandler T, Furmanek S, Carrico R, et al. 23-valent pneumococcal polysaccharide vaccination does not prevent community-acquired pneumonia hospitalizations due to vaccine-type streptococcus pneumoniae. Microorganisms. 2022;10(3):560. doi: 10.3390/microorganisms10030560
   PubMed Web of Science ®Google Scholar
• Dunne EM, Cilloniz C, von Mollendorf C, et al. Pneumococcal vaccination in adults: what can we learn from observational studies that evaluated PCV13 and PPV23 effectiveness in the same population? Arch Bronconeumol. 2023;59(3):157–164. doi: 10.1016/j.arbres.2022.12.015
   PubMedGoogle Scholar
• Heo JY, Seo YB, Choi WS, et al. Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study. J Infect Dis. 2021;225(5):836–845. doi: 10.1093/infdis/jiab474
   Web of Science ®Google Scholar
• Statistisches Bundesamt (Destatis). Consumer price index: Germany reporting date, application [Table 61111]. 2022 [cited 2022 Dec]. Available from: https://www.destatis.de/DE/Home/_inhalt1.html.
   Google Scholar
• LAUER-FISCHER GmbH. WEBAPO® InfoSystem. LAUER-TAXE® Kompetenz online. 2023.
   Google Scholar
• Mangen M-J, Huijts SM, Bonten MJM, et al. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208. doi: 10.1186/s12879-017-2302-3
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–4214. doi: 10.1016/j.vaccine.2004.05.003
   PubMed Web of Science ®Google Scholar
• Robert Koch-Institut. Impfquoten bei Erwachsenen in Deutschland, STIKO: Bestätigung der Pneumokokken-Impfempfehlung. Epidemiologisches Bull. 2020;47:27–30.
   Google Scholar
• IQWiG. Allgemeine Methoden Version 6.1 vom 24.01.2022. 2022. Available from: https://www.iqwig.de/methoden/allgemeine-methoden-v6-1.pdf.
   Google Scholar
• Ständige Impfkommission. STIKO. Modelling methods for predicting epidemiological and health economic effects of vaccinations – guidance for analyses to be presented to the German Standing Committee on vaccination (STIKO). 2016 [last updated 2016 Mar 16]. Berlin.
   Google Scholar
• Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLOS Med. 2020;17(10):e1003326. doi: 10.1371/journal.pmed.1003326
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press; 2006.
   Google Scholar
• Hoshi S-L, Kondo M, Okubo I. Economic evaluation of immunisation programme of 23-valent pneumococcal polysaccharide vaccine and the inclusion of 13-valent pneumococcal conjugate vaccine in the list for single-dose subsidy to the elderly in Japan. PLoS One. 2015;10(10):e0139140.
   PubMed Web of Science ®Google Scholar
• Kolditz M, Tesch F, Mocke L, et al. Burden and risk factors of ambulatory or hospitalized CAP: a population based cohort study. Respir med. 2016;121:32–38. doi: 10.1016/j.rmed.2016.10.015
   PubMed Web of Science ®Google Scholar
• Mendes D, Averin A, Atwood M, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1285–1295. doi: 10.1080/14737167.2022.2134120
   PubMed Web of Science ®Google Scholar
• Olsen J, Schnack H, Skovdal M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23. J Med Econ. 2022;25(1):1240–1254. doi: 10.1080/13696998.2022.2152235
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, et al. Higher-valency pneumococcal conjugate vaccines: an exploratory cost-effectiveness analysis in U.S. Seniors. Am J Preventive Med. 2021;61(1):28–36. doi: 10.1016/j.amepre.2021.01.023
   PubMed Web of Science ®Google Scholar
• Wierzbowski A, Pless R, Hildebrand K. On behalf of the National Advisory Committee on Immunization (NACI). Summary of the NACI Statement on Public Health Level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines. Can Commun Dis Rep. 2023;49(2/3):81–86. doi: 10.14745/ccdr.v49i23a08
   Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32(5):722–732. doi: 10.1177/0272989X12458348
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–677. doi: 10.1177/0272989X12454577
   PubMed Web of Science ®Google Scholar
• Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. (NY): Oxford University Press; 1996.
   Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Med Decis Making. 2012;32(5):690–700. doi: 10.1177/0272989X12455463
   PubMed Web of Science ®Google Scholar
• Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and Immunization decision frameworks: a consensus framework from a European vaccine economics community. PharmacoEconomics. 2016;34(3):227–244. doi: 10.1007/s40273-015-0335-2
   PubMed Web of Science ®Google Scholar
• Croucher NJ, Løchen A, Bentley SD. Pneumococcal vaccines: host Interactions, population dynamics, and design principles. Annu Rev Microbiol. 2018;72(1):521–549. doi: 10.1146/annurev-micro-090817-062338
   PubMedGoogle Scholar
• Masala GL, Lipsitch M, Bottomley C, et al. Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination. J R Soc Interface. 2017;14(136):20170620. doi: 10.1098/rsif.2017.0620
   PubMed Web of Science ®Google Scholar
• Essink B, Sabharwal C, Cannon K, et al. Pivotal phase 3 randomized Clinical trial of the Safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clinl Infect Dis. 2022;75(3):390–398. doi: 10.1093/cid/ciab990
   PubMed Web of Science ®Google Scholar
• Mohapi L, Pinedo Y, Osiyemi O, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. AIDS. 2022;36(3):373–382. doi: 10.1097/QAD.0000000000003126
   PubMed Web of Science ®Google Scholar
• Song J-Y, Chang C-J, Andrews C, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: a randomized phase III trial (PNEU-PATH). Vaccine. 2021;39(43):6422–6436. doi: 10.1016/j.vaccine.2021.08.038
   PubMed Web of Science ®Google Scholar
• Gessner BD, Isturiz R, Snow V, et al. The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumonia. Expert Rev Vaccines. 2021;20(3):269–280. doi: 10.1080/14760584.2021.1889376
   PubMed Web of Science ®Google Scholar
• Hsiao A, Hansen J, Timbol J, et al. Incidence and estimated vaccine effectiveness against hospitalizations for all-cause pneumonia among older US adults who were vaccinated and not vaccinated with 13-valent pneumococcal conjugate vaccine. JAMA Netw Open. 2022;5(3):e221111–e221111. doi: 10.1001/jamanetworkopen.2022.1111
   PubMed Web of Science ®Google Scholar
• Lewnard JA, Bruxvoort KJ, Fischer H, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against medically attended lower respiratory tract infection and pneumonia among older adults. Clin Infect Dis. 2022;75(5):832–841. doi: 10.1093/cid/ciab1051
   PubMed Web of Science ®Google Scholar
• Kim JH, Chun BC, Song JY, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study. Vaccine. 2019;37(21):2797–2804. doi: 10.1016/j.vaccine.2019.04.017
   PubMed Web of Science ®Google Scholar
• Bornheimer R, Shea KM, Sato R, et al. Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PLoS One. 2017;12(10):e0184877. doi: 10.1371/journal.pone.0184877
   PubMed Web of Science ®Google Scholar
• Campling J, Jones D, Chalmers J, et al. Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England. BMJ Open Respir Res. 2020;7(1):e000703. doi: 10.1136/bmjresp-2020-000703
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264–274. doi: 10.1001/jama.2014.18229
   PubMed Web of Science ®Google Scholar
• Hughes GJ, Wright LB, Chapman KE, et al. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect. 2016;144(12):2654–2669. doi: 10.1017/S0950268816000856
   PubMed Web of Science ®Google Scholar
• Myint PK, Hawkins KR, Clark AB, et al. Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort. Epidemiol Infect. 2016;144(4):803–809. doi: 10.1017/S0950268815001971
   PubMed Web of Science ®Google Scholar
• Black CL, Williams WW, Warnock R, et al. Pneumococcal vaccination among medicare beneficiaries occurring after the advisory committee on immunization practices recommendation for routine use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults aged ≥65 years. MMWR Morb Mortal Wkly Rep. 2017;66(27):728–733. doi: 10.15585/mmwr.mm6627a4
   PubMed Web of Science ®Google Scholar
• Morga A, Kimura T, Feng Q, et al. Compliance to advisory committee on immunization practices recommendations for pneumococcal vaccination. Vaccine. 2022;40(15):2274–2281. doi: 10.1016/j.vaccine.2022.03.005
   PubMed Web of Science ®Google Scholar
• Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: a retrospective cohort study. Lancet Reg Health- Eur. 2021;7:100126. doi: 10.1016/j.lanepe.2021.100126
   PubMedGoogle Scholar
• Sprenger R, Häckl D, Kossack N, et al. Pneumococcal vaccination rates in immunocompromised patients in Germany: a retrospective cohort study to assess sequential vaccination rates and changes over time. PLoS One. 2022;17(3):e0265433. doi: 10.1371/journal.pone.0265433
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang D, Ou W. Pneumococcal vaccination patterns among persons aged 65 years or older in the United States: a retrospective database analysis. Vaccine. 2018;36(49):7574–7579. doi: 10.1016/j.vaccine.2018.10.015
   PubMed Web of Science ®Google Scholar